RxDoctor Payments Data

Nicholas Sward, MD

Family Medicine · Kalamazoo, MINPI 1447220918

Payments from drug & device makers

$2,303in general payments, 2019–2025

Across 114 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$588
  • Pfizer$175
  • Amgen$148
  • AstraZeneca$128
  • AbbVie$107
  • Merck$102
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,303100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,303 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$43,969
Medicare patients
136
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide67$96,802
EliquisApixaban93$81,581
OzempicSemaglutide76$79,083
JardianceEmpagliflozin74$78,337
MounjaroTirzepatide61$73,802
JanuviaSitagliptin Phosphate21$26,346
MyrbetriqMirabegron27$20,832
RybelsusSemaglutide14$17,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,642
XareltoRivaroxaban12$13,169
Tresiba Flextouch U-100Insulin Degludec13$11,661
Atorvastatin Calcium566$9,659
MovantikNaloxegol Oxalate11$8,757
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$8,313
Repatha SureclickEvolocumab12$7,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$87$170,605128 claims
Novo NordiskOzempic, Rybelsus$588$96,55190 claims
PfizerEliquis$175$81,58193 claims
Boehringer IngelheimJardiance$98$78,33774 claims
MerckJanuvia$102$26,34621 claims
Astellas Pharma US IncMyrbetriq$55$20,83227 claims
GSKTrelegy Ellipta$53$16,64225 claims
Johnson & JohnsonXarelto$65$13,16912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →